Potent mitochondrial benzodiazepine receptors (MBRs) ligand; Prodrug for its active metabolite bromo-nordazepam

Novel suppressor of endoplasmic reticulum (ER) stress and oxidative stress, preventing protein aggregate accumulation in vitro and in cultured hippocampal HT22 neuronal cells, as well as glutamate-induced oxytosis and erastin-induced ferroptosis

Novel suppressor of endoplasmic reticulum (ER) stress and oxidative stress, preventing protein aggregate accumulation in vitro and in cultured hippocampal HT22 neuronal cells, as well as glutamate-induced oxytosis and erastin-induced ferroptosis

Gilteritinib (ASP2215) hemifumarate is a potent and ATP-competitive FLT3/AXL inhibitor with IC50 of 0.29 nM/0.73 nM, respectively.

Natural suppressor of mesenchymal stem cell (MSC) differentiation

Natural Activator of the Nrf2-Regulated Antioxidant Defense System in SH-SY5Y Cells, Binding to the Subpockets of Keap1 Kelch Domain

First-in-Class, Potent, and Orally Bioavailable NADPH Oxidase Isoform 4 (Nox4) Inhibitor

Novel water solubile prodrug of ICRF-193, penetrating into NVCMs, reaching intracellular concentrations sufficient to induce cytoprotective effects against ANT toxicity

Novel Allosteric Activator of Human Glucokinase in the Absence of Glucose

Novel and potent glucokinase activator (GKA)

First-in-class liver-selective glucokinase activator for the treatment of type 2 diabetes

Novel inhibitor of the cell cycle progression in M-phase; Inhibotor of endosome maturation

Novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

Novel Galactofuranosyltransferase 2 (GlfT2) inhibitor

Second-generation sulfonylurea, promoting the accumulation of fructose 2,6-bisphosphate in hepatocytes

Novel inhibitor of the acetyltransferase activity of Escherichia coli N-acetylglucosamine-1-phosphate-uridyltransferase/glucosamine-1-phosphate-acetyltransferase (GlmU).

Novel potent Glyoxalase 1 (GLO1) inhibitor, demonstrating to penetrate the blood-brain barrier, elevating levels of methylglyoxal in the brain, and reducing depression-like behavior in mice

Novel inhibitor of glyoxalase 1 (Glo1), increasing the cellular methylglyoxal levels in human cells and suppressing the osteoclast formation of mouse bone marrow-derived macrophages

Enteroendocrine hormone, stimulating the growth of intestinal epithelium

Ago-allosteric modulator of human GLP-2R

The first-in-class, ATP-competitive inhibitor of MAPKAPK5

Novel inhibitor of glutaminase 1 (GLS1) with high binding affinity (SPR, Kd = 24 nM; ITC, Kd = 37 nM), exhibiting a similar in vivo antitumor activity as CB839

Novel potent glucose transporter type 4 (GLUT4) translocation activator, showing a significant blood glucose lowering effect in the severe diabetic mice model

Selective inhibitor of human glucose transporter subtype 1/4 (hGLUT1/4)

Selective inhibitor of human glucose transporter subtype 1/4 (hGLUT1/4)

Glucose transporter inhibitor linker for insulin conjugate

Novel glucose transporter (GLUT) inhibitor, exhibited high antitumor potency through the suppression of glucose uptake (IC 50 : 2.5 μM), while not cytotoxic to prostate and mammary epithelial cells

Metabolite of soy isoflavones, promoting the proliferation of bone marrow stromal cells and osteoblasts and suppresses bone turnover

Novel GM3 derivative, showing excellent migration and invasion inhibitory effects in cells and marked antitumor activity in C57BL/6 mice, involving focal adhesion and ECM-receptor interaction signaling pathways

Selective modulator of gamma-aminobutyric acid(A) receptors

Novel potent BCR-Abl PROTAC, inducing degradation and demonstrating in vivo activity

Negative control for GMB-805

Novel Tubulin Polymerization Inhibitor

Novel GluN2A subunit-selective and brain-penetrant positive allosteric modulator (PAM) of The N-methyl-d-aspartate receptor (NMDAR)

Novel potent and selective RORc inverse agonist

Novel Met inhibitor

Novel GluN2A-selective NMDA receptor positive allosteric modulator (PAM)

Novel NMDAR PAM with both an improved pharmacokinetic profile and increased selectivity against AMPARs

Novel inhibitor of nicotinamide phosphoribosyl transferase (NAMPT)

Negative control for GNE-2256

Novel GluN2A-selective NMDA receptor positive allosteric modulator (PAM)

Novel selective CHK1 inhibitor

Novel potent aryl hydrocarbon receptor (AHR) antagonist with the capacity to inhibit both DRE-dependent and -independent activity

Novel Inhibitor of EGF-EGFR Interactions

Novel inhibitor of Plasmodium falciparum, killing both blood- and sexual-stage P. falciparum parasites

Dose dependent up-regulator of the level of E-cadherin in SW620 cells

Natural highly potent HIV latency-reversing agent

Novel inhibitor of Gram-negative lipoprotein trafficking

Novel potent GNMT inducer, inhibiting Huh7 cell growth in vitro and xenograft in vivo

Dual Glycolate Oxidase/Lactate Dehydrogenase A (GO/LDHA) Inhibitor for Primary Hyperoxaluria

Agonist of the GnRH receptor, inducing the secretion of the gonadotropins follicle-stimulating hormone and luteinizing hormone from the pituitary gland and to increase sex hormone production by the gonads

Natural inhibitor of Musashi family of RNA-binding proteins

Antipsychotic and cognitive enhancer; Dopamine D1 and D2 receptor modulator

Natural potent inducer of apoptosis in MCF-7 cell lines

Curcumin analog, exhibiting potent growth suppressive activity in human colorectal carcinoma cells

Novel selective non-steroidal agonist of G-protein bile acid receptor 1 (GPBAR1, also known as TGR5 or M-BAR)

Potent PARP inhibitor

Novel potent GPR120 agonist, exhibiting significant glucose-lowering effect and high selectivity over GPR40

Novel potent GPR52 agonist, dose-dependently suppressing methamphetamine-induced hyperlocomotion in mice

The first orally active GPR52 agonist

Highly potent and specific GPR52 antagonist

Novel, potent, efficacious, and brain-penetrant GPR88 agonist (cAMP EC 50 = 14 nM)

Novel potent GPR88 agonist (EC 50 = 59 nM)

Novel HIV replication blocker (EC 50 = 1.66 μM), being actively against a panel of HIV mutant strains displaying resistance to individual drugs used in antiretroviral therapy

Novel potent and selective ferroptosis inducer, inhibiting glutathione peroxidase 4 (GPX4)

Novel high affinity, potent, and selective stabilizer of the MYC G-quadruplex (G4)., inducing cytotoxicity with corresponding decreased MYC mRNA and altering protein binding to the NHE III1 region

Novel dual G-quadruplex/i-motif binder, binding to and stabilizing both G-quadruplex and i-motif, being effective in both oncogene replication and transcription

Potent TrkA kinase inhibitor

Negative control for GI181771X

Selective and brain penetrant NK1-receptor antagonist

Novel inhibitor of the EGFr and C-erbB-2.

5-HT1B/5-HT1D serotonin receptor antagonist

5-HT3 receptor antagonist

Bacterial siderophore with a diazeniumdiolate ligand system

Potent 5HT3 antagonist

Novel Nrf2 modulator via a thus far uncharacterized mechanism

Natural blocker of the voltage-gated sodium channels located in the cell membrane of neurons

Novel orally available, potent and selective inhibitor of Transient Receptor Potential Ankyrin 1 (TRPA1) with IC50 value less than 10 nM

Novel oral specific TRPV1 antagonist, decreasing bladder overactivity and noxious bladder input in cystitis animal models

Natural Potent Inhibitor for Glioblastoma Stem Cell via Targeting RHOA and PI3K/AKT

Novel potent G-protein-coupled receptor kinase 5 (GRK5) inhibitor

Novel, potent, and selective G protein-coupled receptor kinase 6 (GRK6) inhibitor with an IC50 value of 6 nM against GRK6 and selectivity against a panel of 85 kinases

Novel CCR5 inhibitor, inhibiting the replication of wild-type R5-HIV-1

Novel β-Secretase BACE1 Inhibitor, reversing memory impairments and rescuing age-related cognitive decline

Novel allosteric inhibitor of respiratory syncytial virus (RSV)

Novel potent inhibitor of feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies

Novel Inhibitor of Hepatitis C Viral Infectivity

Novel oral prodrug of GS-441524, inhibiting SARS-CoV-2, including variants of concern (VOC) in cell culture and human airway epithelium organoids

Potent and selective inhibitor of HIV-1 protease, effectively inhibiting protease mutants with amino acid insertions, also inhibiting major aspartyl peptidase 1 (May1), a secreted Cryptococcus neoformans protease

Novel high potent and selective stabilizer of the MYC G-quadruplex (G4)

Glutamate receptor antagonist and radical scavenging agent

Novel allosteric HIV-1 integrase (IN) inhibitor, disrupting formation of mature HIV particles

Novel potent EchA6 inhibitor

Potent inhibitor of AKT kinase

Novel dual H1 and H3 receptor antagonist with a long duration of action

Potent inhibitor of AKT kinase, showing activity against auxotrophic M. tuberculosis and being potentiated with meropenem

Novel inhibitor of polo-like kinase

Novel inhibitor of polo-like kinase

Potent and selective GPR119 agonist

Novel selective inhibitor of MmpL3 mutation

Novel allosteric inhibitor of human immunodeficiency virus (HIV) integrase, blocking viral replication and abnormal multimerization involving specific protein domains

Non-peptidic snail toxin; Activator of the Kv1.1 potassium ion channel

Novel specific P2X(7) receptor antagonist

Novel dual inhibitor of BPTF and Brd4

Potent non-cytotoxic inhinitor of Mycobacterium tuberculosis H37Rv

Potent non-cytotoxic inhinitor of Mycobacterium tuberculosis H37Rv

Novel noncompetitive inhibitor of rTbIPMK

Novel Inhibitor of the Mycobacterium tuberculosis Demethylmenaquinone Methyltransferase MenG

Potent non-cytotoxic inhinitor of Mycobacterium tuberculosis H37Rv

Potent and selective H3 histamine receptor inverse agonist

Novel inhibitor of EPHX2 (epoxide hydrolase 2, alias soluble epoxide hydrolase or sEH), up-regulating cytoprotective genes and down-regulating proinflammatory cytokine production

Novel potent, metabolically stable and centrally penetrant PPARγ partial agonist

Novel competitive inhibitor of rTbIPMK with respect to Ins(1,4,5)P3

Novel selective non-imidazole histamine H 3 receptor antagonist

Novel AKT Inhibitor, Enhancing Anti-Tumor Effects in Combination with the MEK Inhibitor

Novel insulin-like growth factor 1 receptor inhibitor, binding to a novel region of the GRK active site cleft that could likely be exploited to achieve more selectivity

Novel inhibitor of T. brucei IPMK, partially inhibiting rTbIPMK activity

Inhibitor of insulin receptor, also tageting IGF-1R and ALK

Selective inhibitor of iE-DAP-stimulated IL-8 release via the NOD1 signaling pathway

Novel highly potent, reversible soluble epoxide hydrolase (sEH) inhibitor, exhibiting potent cell-based activity, a concentration-dependent inhibition of the conversion of 14,15-EET to 14,15-DHET, attenuating cigarette smoke-induced inflammation by both i

Novel S1P1 receptor agonist

Novel I-kappa-B kinase-3 (IKK3) inhibitor

Novel selective histamine H3 receptor antagonist

Specific ATPase competitive kinesin-5 inhibitor

Betulin derivative as antitumor agent

Novel selective inhibitor of G protein-coupled receptor kinase 2 (GRK2)

Novel potent and selective, SAM-competitive inhibitor of SMYD3

Novel human immune virus (HIV) maturation inhibitor

Novel inhbitor of protein kinase GRK1/2/5 and PKA

Novel quaternized GSK-3008348 derivative, acting as a highly selective αvβ6 Integrin Inhibitor

Novel potent RORγ inverse agonist

Potent and selective antagonist of P2X7 receptor

Novel selective inhibitor of G protein-coupled receptor kinase 2 (GRK2)

Promiscuous kinase inhibitor, a close analog of CTx-0294885

Novel agonist of toll-like receptor 2 (TLR2), stimulating the release of G-CSF in activated THP-1 cells, peripheral blood mononuclear cells, and human umbilical vein endothelial cells

Novel selective non-imidazole histamine H 3 receptor antagonist

Novel lysine specific histone demethylase 1 (LSD1) inhibitor, exhibiting high selectivity to LSD1 over MAOs

Novel inhibitor of prolyl hydroxylase (PHD) domain-containing enzyme

Novel anti-TB agent against Mycobacterium tuberculosis and Mycobacterium bovis BCG, targeting MmpL3 and inhibiting EchA6

Novel DNMT1-selective inhibitor (IC 50 = 0.11 ± 0.02 µM)

Novel highly potent cell-permeable, reversible, ATP-competitive inhibitor of GSK-3 (IC50 = 0.4 and 0.6 nM for GSK-3α and GSK-3β, respectively)

GSK3-IN-3 is a mitophagy inducer, inducing Parkin-dependent mitophagy. GSK3-IN-3 is also a GSK-3 inhibitor with an IC50 value of 3.01 μM. GSK3-IN-3 is non-ATP nor substrate competitive and is neuroprotective against 6-OHDA.

Potent and irreversible inhibitor of GSK3

First-in-Class GSK-3β/HDAC Dual Inhibitor as a Disease-Modifying Agent To Combat Alzheimer’s Disease

Negative control for GSK4027

Novel specific inhibitor of polo-like kinase 1 (PLK-1), inducing cell death by causing cell cycle arrest at G2/M phase by competing with the ATP binding site of PLK-1 thus leading to apoptosis

Novel, Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitor

Novel selective inhibitor of G protein-coupled receptor kinase 2 (GRK2)

Novel highly potent and selective non-peptide oxytocin receptor antagonist

Novel potent EchA6 inhibitor

Novel inhibitor of the Ribonuclease H Activity of HIV-1 Reverse Transcriptase

Potent polo-like kinase 1 (PLK1) inhibitor

Novel ATM inhibitor with cancer cell specific radiosensitization activity

Novel, soluble, permeable, and selective BRD7/9 inhibitor

Novel PCAF/GCN5 degrader, modulating PCAF/GCN5 immune cell function through a PROTAC approach

Negative control for GSK699

Novel stabilizer of Zα 1 -antitrypsin, blocking Zα 1 -antitrypsin polymerisation in vitro, reducing intracellular polymerisation and increasing the secretion of Zα 1 -antitrypsin threefold in an iPSC model of disease

Novel potent inhibitor of EchA6

Novel Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor

Negative control for GSK789

Novel potent and selective BET pan-BD2 inhibitor

Novel agonist of the orphan nuclear receptors steroidogenic factor-1 (SF-1, NR5A1) and liver receptor homologue-1 (LRH-1, NR5A2)

Selective glucocorticoid receptor agonist (SEGRA)

Negative control for GSK8814

Highly potent, selective, SAM-competitive, and cell-active EZH2 inhibitor

Antimalarial

Negative control for GSK073

Novel potent protein kinase C-related kinase 1 (PRK1) inhibitor with IC50 of 40±8.7 nM)

Novel potent inhibitor of bacterial type IIA topoisomerases

Selective inhibitor of iE-DAP-stimulated IL-8 release via the NOD1 signaling pathway

Potent inhibitor of bacterial type IIA topoisomerases

Novel potent transrepression-selective liver X receptor modulator with anti-inflammatory activity

Negative control as an inactive IDH1 inhibitor

Next-generation NSAID-like γ-secretase modulator (GSM) with improved in vitro potency and brain penetration, effectively lowering Aβ42 production in cells and in amyloid precursor protein transgenic mice

Novel hepatitis B surface antigen (HBsAg) inhibitor for the treatment of hepatitis B virus infection

Novel potent histamine H3 receptor antagonist

Novel broad-spectrum inhibitor of coronavirus and enterovirus replication, targeting the main protease (Mpro or 3CLpro)

First-In-Class Antagonist against the Adrenomedullin-2 (AM2) Receptor

Inhibitor of vasoconstrictor responses to sympathetic nerve stimulation, potentiating the actions of adrenaline and noradrenaline, increasing the blood glucose concentration and decreasing the appetite

Novel inhibitor of the activation of nuclear factor (NF)-κB signaling in bone marrow-derived dendritic cells, significantly inhibiting LPS-induced IL-12p40 and TNF-α gene expression, IκBα degradation, and NF-κB DNA binding activity in BMDCs, attenuating c

Acyl-CoA, inhibiting cholesterol acyltransferase

Natural inhibitor of 3C-like protease (3CLpro), targeting SARS-CoV-2 3CLpro, SARS-CoV 3CLpro and MERS-CoV 3CLpro

Potent inhibitor of cabonic anhydrase 2 (CA2)

Negative allosteric modulator of human P2X7 and a positive allosteric modulator of rat P2X7

Potent inhibitor of adipocyte differentiation and weak partial agonist of

Novel Selective and Nonpeptidomimetic Proteasome Inhibitor As an Antimalarial, specifically inhibiting the proteasome activity in P. falciparum

Novel agonist for retinoid X receptor

Inhibotor of active Vaccinia-Related Kinases (VRK)

Novel inhibitor of CDK

Novel selective and soluble inhibitor of tumor necrosis factor-alpha converting enzyme (TACE)

Potent and selective full agonist for peroixisome proliferator-activated receptor-alpha

Novel potent RET kinase inhibitor

Potent TrkA kinase inhibitor

Novel agonist at the adenosine A1 receptor

Orally active, nonsteroidal tamoxifen derivative and a ligand for the estrogen receptors (ERs), steroid receptor members of the nuclear receptor superfamily of transcription factors

Inhibitor of Mer Kinase, also inhibiting EGFR

Novel VEGFR inhibitor, also a moderate inhibitor of BET proteins with an IC 50 value of 4.6 μM for BRD4(1)

Potent inhibitor of PfDHODH, showing greater than 4,000-fold selectivity for the malarial enzyme

Novel inhibitor of EGFR

Novel inhibitor of firefly luciferase derived from Photinus pyralis (FLuc), the most widely used luciferase